ABSTRACT
With the growing development of modern agriculture and industry, groundwater is facing more and more complex contaminants. One such contaminant is per- and polyfluoroalkyl substances (PFASs), which pose a potential risk to human health, particularly for those who rely on groundwater as their primary source of drinking water. In this study, we conducted a comprehensive investigation on the occurrence, spatial distribution, and source apportionment of PFASs in shallow (<60 m) and deep (>80 m) groundwater samples from a reclaimed water irrigation area in Beijing's suburbs. Our results showed that the average total PFAS concentration (∑10PFAS) for all samples was 10.55 ± 7.77 ng/L, ranging from 1.05 to 34.28 ng/L. The dominant congeners were PFBA, PFOA, and PFBS. No significant linear relationship was observed between PFAS concentrations and the well depth. However, the averaged ΣPFASs in groundwater were highest in the uppermost layer and declined sharply to a few ng/L in the deep aquifer below 80 m. PFASs showed elevated concentration in shallow aquifers in 9 out of 11 paired wells, indicating an overall descending trend of PFASs with increasing aquifer depth. The spatial distribution of PFASs was highly heterogeneous and showed different patterns in shallow and deep groundwater, which may be related to the complicated attenuation behavior of PFAS compounds when they transport and diffuse through overlapping aquifer layers. The influence of the landfill on groundwater PFASs was most pronounced within a 5 km radius. Source apportionment results indicated that reclaimed water irrigation is the main non-point source of PFASs in shallow groundwater. In contrast, deep groundwater is primarily subject to point sources and lateral recharge flow. This investigation of PFASs in shallow and deep wells provides a foundation for further exploration of PFASs transportation and risk prevention in regions where groundwater is a major water resource for domestic and industrial development.
ABSTRACT
@#Background & Objective: Endovascular treatment is the widely accepted treatment for patients with anterior circulation stroke within 6 hours of onset of stroke. We aimed to evaluate the advantages of endovascular treatment compared to standard medical treatment in treating patients with anterior circulation stroke beyond the 6-hour therapeutic window. Methods: We reviewed the literature concerning endovascular treatment versus medical treatment beyond the 6-hour therapeutic window. Using random-effects meta-analysis, we evaluated the following outcomes: modified Rankin scale in the three-month follow-up [excellent outcome (mRS≤1), functional independence (mRS≤2), moderate outcome(mRS≤3)], recanalization rate at 24 hours, mortality at 90 days or in-hospital, symptomatic intracranial hemorrhage, parenchymal hematoma type 2 and hemorrhagic infarction 1. Results: Four studies including 642 patients were evaluated. Endovascular treatment was associated with higher odds of excellent outcome (OR 2.55; 95% CI 1.48 to 4.41,), functional independence (OR 3.64; 95% CI 2.43 to 5.45), moderate outcome (OR 2.70; 95% CI 1.95-3.74) and recanalization rate at 24 hours (OR 8.81; 95%CI 2.81 to 27.69) compared to MT. No difference in the rates of mortality, symptomatic intracranial hemorrhage, parenchymal hematoma type 2 or hemorrhagic infarction 1 was found between the 2 groups. Studies using strict perfusion imaging inclusion selection showed better moderate outcome in comparison to the studies without perfusion imaging inclusion selection (P <0.012). Conclusion: Our study highlights the superiority of endovascular treatment over standard medical treatment alone for treating patients with anterior circulation stroke beyond 6 hours since stroke onset, although more studies are required for further investigation. Standard of strict selection for eligible patients before endovascular treatment should be based on DAWN or DEFFUSE 3 inclusion criteria.
ABSTRACT
SUMMARY Therapy-related acute myeloid leukemia (tAML) is one of the two forms of secondary acute myeloid leukemia, with one derived from de novo myelodysplastic syndrome (MDS) and the other from exposure to environmental or therapeutic agents such as radiation and toxins. There has been a marked increase in the number of incidences of therapy-related acute myeloid leukemia. It has become a distinctive disease because of its etiology and genetic tumorigenesis. The majority of tAML resulting from the use of cytotoxic agents can be divided into two groups based on the drugs administered to the patient. The first group includes the use of alkylating agents, and the second group includes agents that bind to the enzyme DNA-topoisomerase Ⅱ. Due to the unfavorable outcome of the disease and the need for prompt intensive treatment, a timely accurate diagnosis of tAML is critical to patient care. Cytogenetic study can detect abnormalities most commonly associated with tAML and thus providing important diagnostic information. However, utilizing cytogenetic analysis alone cannot guarantee prompt and accurate results. In this study, an interesting case with therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/tAML) will be presented. A laboratory diagnostic strategy for tAML laboratory diagnosis will also be proposed.
ABSTRACT
SUMMARY Constitutional full trisomy 21 is a common disorder in which abnormal spermatogenesis has been previously described. However, constitutional mosaic trisomy 21 in an otherwise normal but infertile male has not been explored. We report a case with low level mosaic trisomy 21 in a non-syndrome but azoospermic patient. We also propose that the patient's azoospermia may be related to the constitutional mosaic trisomy 21 and thus resulting in a late onset of testicular failure.
